Crinetics Pharmaceuticals CRNX Business Segments — Loss on equity method investment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — loss on equity method investment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — loss on equity method investment?
- Crinetics Pharmaceuticals (CRNX) reported business segments — loss on equity method investment of $0 in Q4 2025.
- How has Crinetics Pharmaceuticals's business segments — loss on equity method investment changed year-over-year?
- Crinetics Pharmaceuticals's business segments — loss on equity method investment increased by 100.0% year-over-year, from -$117.5K to $0.
- What is the long-term trend for Crinetics Pharmaceuticals's business segments — loss on equity method investment?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's business segments — loss on equity method investment has grown at a -100.0% compound annual growth rate (CAGR), from -$5.2M to $0.
- What does business segments — loss on equity method investment mean?
- Records the company's share of losses from investments in other entities where it exercises significant influence but does not have full control. This metric highlights the financial impact of strategic partnerships or minority stakes in external ventures. It is used to assess the performance and risk associated with the company's external investment portfolio.